Samina Khan, MD
Internal Medicine · West Orange, NJNPI 1992764906
Payments from drug & device makers
Across 17 payments — averaging $83.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vertex$1K
- Medtronic$141
- Lilly USA, LLC$24
- Novo Nordisk$20
- Boehringer Ingelheim$19
- Merck$13
- plus $13 from 1 others
What the payments were for
- Travel & lodging$1,16882%
- Food & beverage$23116%
- Education$191%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vertex | 6 | $1,189 |
| Medtronic(2 entities) | 5 | $141 |
| Lilly USA, LLC | 2 | $24 |
| Novo Nordisk | 1 | $20 |
| Boehringer Ingelheim | 1 | $19 |
| Merck | 1 | $13 |
| GSK | 1 | $13 |
How this compares
$1,418 in reported general payments places this provider in the 70th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 41 | $54,861 |
| JardianceEmpagliflozin | 46 | $48,959 |
| EliquisApixaban | 33 | $42,140 |
| MounjaroTirzepatide | 26 | $41,742 |
| OzempicSemaglutide | 32 | $36,433 |
| JanumetSitagliptin Phos/Metformin Hcl | 17 | $19,185 |
| Incruse ElliptaUmeclidinium Bromide | 16 | $11,937 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 13 | $11,299 |
| Breo ElliptaFluticasone/Vilanterol | 22 | $9,746 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 144 | $4,662 |
| Atorvastatin Calcium | 397 | $3,217 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 24 | $2,439 |
| Levothyroxine Sodium | 198 | $2,105 |
| Rosuvastatin Calcium | 203 | $1,828 |
| Amlodipine Besylate | 296 | $1,484 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia, Janumet | $13 | $74,04658 claims |
| Boehringer IngelheimJardiance | $19 | $48,95946 claims |
| Lilly USA, LLCMounjaro | $24 | $41,74226 claims |
| Novo NordiskOzempic | $20 | $36,43332 claims |
| GSKIncruse Ellipta, Breo Ellipta | $13 | $21,68238 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in West Orange
- Sanjiv SharmaToms River$33.9M
- Jeffrey CarsonNew Brunswick$13.8M
- Samer HaddadHamilton$6.8M
- Magdy ShenoudaWall$3.7M
- Samar HameedLivingston$3.6M
- Jane RohlfTrenton$2.7M
- Mohammed NisarEdison$2.6M
- Michael CasserNew Milford$2.2M
- Sumitha ReddyHamilton$2M
- Helio PedroNewark$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.